1) 公益財団法人がん研究振興財団編 : がんの統計 '13 (www.fpcr.or.jp/publication/pdf/gantoukei13.pdf)
2) 大腸癌研究会編 : 大腸癌治療ガイドライン 医師用 2014年版, 金原出版, 2014
3) Sackett, DL et al : Evidence based medicine : what it is and what it isn't. BMJ 312 : 71-72, 1996
4) de Gramont, A et al : Randomized trial comparing monthly low-dose leucovorin and fluorouracil bolus with bimonthly high-dose leucovorin and fluorouracil bolus plus continuous infusion for advanced colorectal cancer : a French intergroup study. J Clin Oncol 15 : 808-815, 1997
5) Shimada, Y et al : Phase II study of CPT-11, a new camptothecin derivative, in metastatic colorectal cancer. CPT-11 Gastrointestinal Cancer Study Group. J Clin Oncol 11 (5) : 909-913, 1993
6) Saltz, LB et al : Irinotecan plus fluorouracil and leucovorin for Metastatic Colorectal Cancer. N Engl J Med 343 : 905-914, 2000
7) Douillard, JY et al : Irinotecan combined with fluorouracil compared with fluorouracil alone as firstline treatment for metastatic colorectal cancer : a multicentre randomised trial. Lancet 355 : 1041-1047, 2000
8) de Gramont, A et al : Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 18 (16) : 2938-2947, 2000
9) Goldberg, RM et al : A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J Clin Oncol 22 (1) : 23-30, 2004
10) Muro, K et al : Irinotecan plus S-1 (IRIS) versus fluorouracil and folinic acid plus irinotecan (FOLFIRI) as second-line chemotherapy for metastatic colorectal cancer : a randomised phase 2/3 non-inferiority study (FIRIS study). Lancet Oncol 11 : 853-860, 2010
11) Yamada, Y et al : Leucovorin, fluorouracil, and oxaliplatin plus bevacizumab versus S-1 and oxaliplatin plus bevacizumab in patients with metastatic colorectal cancer (SOFT) : an open-label, non-inferiority, randomised phase 3 trial. Lancet Oncol 14 (13) : 1278-1286, 2013
12) Saltz, LB et al : Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer : A randomized phase III study. J Clin Oncol 26 : 2013-2019, 2008
13) Petrelli, F et al : FOLFIRI-bevacizumab as firstline chemotherapy in 3500 patients with advanced colorectal cancer : a pooled analysis of 29 published trials. Clin Colorectal Cancer 12 : 145-151, 2013
14) Bennouna, J et al : Continuation of bevacizumab after first progression in metastatic colorectal cancer (ML18147) : a randomised phase 3 trial. Lancet Oncol 14 : 29-37, 2013
15) Van Cutsem, E et al : Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med 360 : 1408-1417, 2009
16) Heinemann, V et al : FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3) : a randomised, open-label, phase 3 trial. Lancet Oncol 15 (10) : 1065-1075, 2014
17) Venook, AP et al : CALGB/SWOG 80405 : Phase III trial of irinotecan/5-FU/leucovorin (FOLFIRI) or oxaliplatin/5-FU/leucovorin (mFOLFOX6) with bevacizumab (BV) or cetuximab (CET) for patients (pts) with KRAS wild-type (wt) untreated metastatic adenocarcinoma of the colon or rectum (MCRC). J Clin Oncol 32 : 5s (suppl ; abstr LBA3), 2014
18) Douillard, JY et al : Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer. N Engl J Med 369 : 1023-1034, 2013
19) Grothey, A et al : Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT) : an international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet 381 : 303-312, 2013
20) Yoshino, T et al : TAS-102 monotherapy for pretreated metastatic colorectal cancer : a doubleblind, randomised, placebo-controlled phase 2 trial. Lancet Oncol 13 : 993-1001, 2012